HUMAN CASE SERIES

EX-US HUMAN CASE SERIES: EARLY CLINICAL SIGNAL ACROSS NEUROPATHY TYPES

6 of 8 subjects reported marked symptom reduction with topical CFB-001, including 3 of 5 with CIPN

Patient-reported symptom score (0–10): before vs. on CFB-001 (last reported)

Non-responders: two CIPN subjects (one ~10 years after oxaliplatin; one on a Keytruda-based regimen). Subject #3 improved, but relief lasted ~3-4 hours per application. Subject #1 score shown after the dose was raised to 1.0% 4x/day during oxaliplatin dose escalation.

Uncontrolled, open-label, ex-US case series; patient-reported symptom scores. CFB-001 gel 0.5–2.0%, 2–4x daily. Not a controlled clinical trial; results may not be representative of future clinical study outcomes.

Report abuse